Xeris Biopharma (XERS) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Xencor (XNCR) has outperformed Xeris Biopharma (XERS) over the past year, gaining 88.6% versus a gain of 28.0%. Over five years, XERS leads with a +424.0% price change compared with -36.0% for XNCR. Xeris Biopharma is the larger company by market cap ($1.91 billion vs $1.83 billion), about 1.0 times the size.
Xeris Biopharma converts more of its revenue into profit, with a net margin of 0.2% versus -73.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | XERS | XNCR |
|---|---|---|
| Share price | $10.48 | $24.63 |
| Market cap | $1.91B | $1.83B |
| 1-day change | +2.85% | +0.53% |
| YTD return | +33.50% | +60.88% |
| 1-year return | +27.96% | +88.59% |
| 5-year return | +424.00% | -35.98% |
| Forward P/E | 28.32 | — |
| EPS (TTM) | $-0.10 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $291.85M | $125.58M |
| Revenue growth (YoY) | +43.72% | +13.65% |
| Net income (latest FY) | $554.00K | $-91.92M |
| Gross margin | 85.41% | — |
| Operating margin | 8.53% | -141.35% |
| Net margin | 0.19% | -73.20% |
| 52-week high | $11.33 | $30.61 |
| 52-week low | $5.25 | $10.38 |
| Distance from 52-week high | -7.50% | -19.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +22.71% | +27.57% |
| Average volume | 2.18M | 1.32M |
| Shares outstanding | 182.32M | 74.35M |
| Employees | 435 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed XERS by 60.6 percentage points over the past year.
- Xeris Biopharma is more profitable, keeping 0.2 cents of every revenue dollar as net income versus -73.2 cents for Xencor.
- Xeris Biopharma grew revenue faster in its latest fiscal year (+43.72% vs +13.65%).
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
XERS vs XNCR FAQ
Which is bigger, Xeris Biopharma or Xencor?
Xeris Biopharma (XERS) is larger, with a market capitalization of $1.91B compared with $1.83B for Xencor (XNCR).
Which stock has performed better over the past year, XERS or XNCR?
XNCR returned +88.59% over the past 12 months, compared with +27.96% for XERS (price return, excluding dividends). Past performance does not predict future results.
Are Xeris Biopharma and Xencor in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.